News Column

Reports from V. Bansal et al Highlight Recent Findings in Vaccines (Evaluation of synergistic effect of biodegradable polymeric nanoparticles and...

August 6, 2014



Reports from V. Bansal et al Highlight Recent Findings in Vaccines (Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy)

By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Immunization have been published. According to news reporting originating in Tamil Nadu, India, by NewsRx journalists, research stated, "Aluminum based adjuvants have been used widely to induce long lasting protective immunity through vaccination. But reported incidences of toxicity and side effects of aluminum have raised concerns regarding their safety in childhood vaccines."

The news reporters obtained a quote from the research, "The present study demonstrates the synergistic effect of admixture of polylactic acid-polyethylene glycol (PLA-PEG) based biodegradable nanoparticles (NPs) and aluminum phosphate as a potential adjuvant system using tetanus toxoid (TT) as a model antigen. The immunological activity of the admixture formulation was maintained up to 180 days of storage at 5 degrees C +/- 3 degrees C. Percent adsorption/encapsulation of tetanus toxoid increased to nearly 90% in admixture formulation as compared to 55% in conventional vaccine. Admixture preparation (PLA-PEG-Al 0.2 mg-TT and PLA-Al 0.2 mg-TT) showed 80% and 50% survival respectively, even at 180 days as compared to 30% survival observed in the conventional tetanus vaccine."

According to the news reporters, the research concluded: "The present study established the feasibility to formulate a dosage form with improved efficacy and reduced aluminum concentration for vaccination."

For more information on this research see: Evaluation of synergistic effect of biodegradable polymeric nanoparticles and aluminum based adjuvant for improving vaccine efficacy. International Journal of Pharmaceutics, 2014;471(1-2):377-384. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)

Our news correspondents report that additional information may be obtained by contacting V. Bansal, BCG Vaccine Lab, Madras, Tamil Nadu, India. Additional authors for this research include M. Kumar, M. Dalela, H.G. Brahmne and H. Singh (see also Immunization).

Keywords for this news article include: Asia, India, Drugs, Therapy, Vaccines, Tamil Nadu, Immunization, Nanoparticle, Nanotechnology, Tetanus Toxoid, Biological Products, Emerging Technologies

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters